Patients 60 years of age or older with CAD and baseline systolic BP > 150 mm Hg randomized to a treatment strategy on the basis of either atenolol/hydrochlorothiazide or verapamil-SR ( sustained release ) / trandolapril in INVEST ( INternational VErapamil SR Trandolapril STudy ) were categorized into 3 groups on the basis of achieved on-treatment systolic BP : group 1 , < 140 mm Hg ; group 2 , 140 to < 150 mm Hg ; and group 3,150 mm Hg .